The PPM1D gene is aberrantly amplified in a range of common cancers and encodes a protein phosphatase that is a potential therapeutic target. However, the issue of whether inhibition of PPM1D in human tumour cells that overexpress this protein compromises their viability has not yet been fully addressed. We show here, using an RNA interference (RNAi) approach, that inhibition of PPM1D can indeed reduce the viability of human tumour cells and that this effect is selective; tumour cell lines that overexpress PPM1D are sensitive to PPM1D inhibition whereas cell lines with normal levels are not. Loss of viability associated with PPM1D RNAi in human tumour cells occurs via the activation of the kinase P38. To identify chemical inhibitors of PPM1D, a high-throughput screening of a library of small molecules was performed. This strategy successfully identified a compound that selectively reduces viability of human tumour cell lines that overexpress PPM1D. As expected of a specific inhibitor, the toxicity to PPM1D overexpressing cell lines after inhibitor treatment is P38 dependent. These results further validate PPM1D as a therapeutic target and identify a proof-of-principle small molecule inhibitor.
Introduction
The phosphorylation and dephosphorylation of proteins plays a vital regulatory role in multiple cellular pathways including those dysfunctional in cancer. The human genome harbours over 500 putative protein kinases (Manning et al., 2002) , whereas protein dephosphorylation is controlled by four structurally distinct protein families that include the serine/threonine phosphatase families PPP and PPM (Gallego and Virshup, 2005) . PPM1D (also known as PP2Cd and WIP1) is a member of the PPM family (Fiscella et al., 1997) , which is characterized by Mg 2 þ /Mn 2 þ -dependent activity and relative insensitivity to okadaic acid. PPM1D is encoded by a putative oncogene that is amplified in multiple cancer types Li et al., 2002; Hirasawa et al., 2003; Saito-Ohara et al., 2003; Mendrzyk et al., 2005; Shreeram et al., 2006) , including 11-16% of human primary breast cancers, most of which express wild-type P53 Li et al., 2002) .
PPM1D was originally described as a phosphatase that is induced in a P53-dependent manner in response to DNA damage. PPM1D activation results in negative regulation of P53 function and other tumour suppressor pathways by selective inactivation of P38 kinase (Fiscella et al., 1997; Takekawa et al., 2000; Bulavin et al., 2004) . Additional functions for PPM1D include the regulation of the base excision pathway of DNA repair (Lu et al., 2004) , progesterone receptor function (Proia et al., 2006) , the homoeostatic regulation of the checkpoint kinases CHK1 and CHK2 (Lu et al., 2005; Fujimoto et al., 2006; Nannenga et al., 2006; OlivaTrastoy et al., 2006; Yoda et al., 2006; Yu et al., 2006) and the activation of ataxia-telangiectasia mutated (Shreeram et al., 2006) , all of which may also contribute to the oncogenic effects of PPM1D overexpression. Mice deficient in Ppm1d are viable, with only minor defects in immune function and spermatogenesis (Choi et al., 2002) . However, these animals are resistant to mammary tumours induced by mouse mammary tumor virus-driven cHras1 or cNeu as well as to spontaneous tumour formation (Bulavin et al., 2004; Nannenga et al., 2006) . Furthermore, Ppm1d À/À mouse embryonic fibroblasts are resistant to oncogenic transformation through activation of the tumour suppressors p16
Ink4a and p19
Arf via p38 (Bulavin et al., 2004) . A combination of factors has led to the consideration of PPM1D as a selective therapeutic target (Harrison et al., 2004) . First, despite having recognizably conserved elements of the PP2C phosphatase domain, PPM1D is distantly related in amino-acid sequence to the rest of this phosphatase subfamily, suggesting the possibility of specific inhibition. Second, genetic ablation of Ppm1d is well tolerated in mice suggesting minimal side effects associated with PPM1D inhibition.
Third, Ppm1d
À/À mice are resistant to tumorigenesis. Finally, the aberrant overexpression of PPM1D in tumours may provide a significant therapeutic index. However, phosphatases have traditionally been regarded as being difficult to specifically inhibit with small molecules (Harrison et al., 2004) . Nevertheless, chemical and cyclic phosphopeptide substrate mimetic inhibitors of PPM1D have been isolated (Belova et al., 2005; Yamaguchi et al., 2006) and although these are not promising drug development candidates and questions remain as to their specificity, they do provide evidence that inhibitors can be discovered.
To further validate PPM1D as a therapeutic target, we have studied the effects of PPM1D inhibition in human tumour cells. A high-throughput screening assay was developed to identify small molecule chemical inhibitors of PPM1D. We identified one small molecule that showed both efficacy and also selectivity towards cells overexpressing PPM1D.
Results
Reduction of high-level PPM1D expression can selectively inhibit the growth of human tumour cells PPM1D amplification occurs in a wide range of cancers. This observation has led to the hypotheses that PPM1D overexpression is a causative factor in tumorigenesis and that inhibition of PPM1D may be of therapeutic benefit. However, validation of PPM1D as a therapeutic target in cancer has focused on the reduction of normal Ppm1d levels in the mouse using gene targeting (Bulavin et al., 2004; Nannenga et al., 2006) or, in one instance, transgenic overexpression of PPM1D in the mouse breast epithelium (Demidov et al., 2007) . The proposed model of PPM1D involvement in cancer involves overexpression in human tissue and, therefore, an important proof-of-principle experiment is to show that inhibition of aberrantly elevated, but not basal, levels of PPM1D can be selectively lethal in human tumour cells.
To model specific inhibition of high levels of PPM1D and examine the effects on cell survival, we utilized RNA interference (RNAi). We developed pSUPERbased constructs (Brummelkamp et al., 2002) that express short-hairpin RNAs that target PPM1D by RNAi (Figure 1a ). The effect of PPM1D silencing in a range of human tumour cell lines was then analysed using a colony formation assay (Figures 1b and c) . Reducing PPM1D expression was found to almost completely abolish colony formation by the tumour cell lines MCF-7, KPL-1 and MCF-3B. However, two cell lines, 293T (embryonic kidney) and HeLa (cervical cancer), were unaffected by PPM1D RNAi silencing.
To investigate the relationship between sensitivity to PPM1D RNAi silencing and PPM1D overexpression, levels of the phosphatase were assessed. All three cell lines sensitive to PPM1D silencing (MCF-7, KPL-1 and MCF-3B) express high levels of PPM1D, whereas 293T and HeLa cells (which were insensitive to PPM1D silencing) express only modest amounts of PPM1D (Figure 1d ), supporting the hypothesis that PPM1D inhibition may be of selective therapeutic benefit in human tumours where PPM1D is overexpressed.
PPM1D has been previously shown to dephosphorylate P38 at threonine 180 , a residue essential for P38 activity (Takekawa et al., 2000) . To investigate the mechanism of cell death upon PPM1D RNAi silencing, we examined the effects of treating MCF-7 cells with the specific P38 inhibitor SB203580 (Fitzgerald et al., 2003) . These experiments indicated that SB203580 was able to partially rescue the loss of cell viability observed in MCF-7 cells transfected with pSUPER-PPM1D (Figure 1e) , suggesting that the cell death observed is mediated, at least in part, by P38 kinase activity.
High-throughput screen to identify chemical inhibitors of PPM1D
The application of AlphaScreen technology for highthroughput enzymatic assays has been described previously (Von Leoprechting et al., 2004; Warner et al., 2004; Burns et al., 2006) . We adapted this assay format for the identification of inhibitors of PPM1D phosphatase activity. We used recombinant PPM1D (rPPM1D) in this assay and confirmed its activity by measuring the ability of rPPM1D to dephosphorylate phospho-P38 in an Mn 2 þ -dependent manner ( Figure 2a ). Our AlphaScreen assay also utilized a biotinylated phospho-P38 peptide representing Phe 169 -Ile 193 of P38 and a phosphospecific anti-P38 antibody. A 10-to 25-fold greater specificity of the antibody for the phosphorylated substrate compared to its non-phosphorylated control was achieved (Figure 2b ). AlphaScreen signal was reduced in a concentration-and time-dependent manner in the presence of rPPM1D but was relatively unchanged in the absence of enzyme (Figure 2c ). The conditions for the final assay (see 'Materials and methods') included an enzyme concentration of 2 nM and a reaction time of 20 min, which generated signal within the linear range and caused 50-60% depletion of the substrate. Approximately 65 500 compounds were screened at a final concentration of 30 mM. b-Glycerophosphate (IC 50 ¼ 10 mM) was used as a positive control. All plates passed the quality control criteria of Z 0 factor >0.5 (Zhang et al., 1999) , with an overall plate coefficient of variation of o10% (Supplementary Figure 1) .
Hit identification and validation
Each compound was assayed using the AlphaScreen format a total of four times. Fifty-four compounds were identified as confirmed hits (30-70% inhibition). Fifteen hits from the NCI Diversity Set included NCI 119889-W, a previously reported inhibitor of PPM1D (Belova et al., 2005) . Given that this small molecule has been shown not to be selective for cells with high expression of PPM1D (Belova et al., 2005) , this hit was not pursued. Nineteen of the compounds were commercially available and of these six were active in both the primary AlphaScreen assay and in a Delfia phosphatase assay (see 'Materials and methods'). The latter was carried out in the presence and absence of Triton X-100 (0.01%, v/v) (Ryan et al., 2003) PPM1D-eGFP inhibition rescues PPM1D RNAi silencing-mediated cell death. MCF-7 cells were treated with SB203580 (10 mM) for 24 h before transfection with either pSUPER-control or pSUPER-PPM1D. SB203580 (10 mM) results in a 50% inhibition of P38 phosphorylation of ATF2 (data not shown). Use of SB203580 at >10 mM inhibited the transfection procedure (data not shown). Cells were retreated with SB203580 24 h after transfection. Cells were counted at 48 h post-transfection and the SF was calculated for each transfection (according to the number of cells originally plated). Each bar represents three independent experiments and the error bars, two standard errors of the mean.
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to exclude compounds with non-specific aggregating effects (McGovern et al., 2002 (McGovern et al., , 2003 . The chemical structures of the confirmed hits and their IC 50 values are shown in Figure 3 . Two of these compounds (CC000913 and CCT0010971) are planar, pentacyclic compounds that have the potential for DNA intercalation. CCT021600 is a thiobarbituric acid derivative. Thiobarbituric acid is well known to convert to thiobarbituric acid reactive substances (TBARS) under oxidative stress (Cheng et al., 2006) . The chemical stability of the exocyclic imine group in CCT061244 is doubtful, leaving CCT007093 and CCT071835 as the most promising hit compounds. Thioxanthones related to CCT071835 have been reported as anti-tumour agents in an NCI screen (albeit by apparent complex formation with DNA (Archer et al., 1982) ). A compound representing the parent ring system of CCT071835 is commercially available (Thioxanthen-9-one, T34002, Sigma-Aldrich, Gillingham, UK) and showed reduced potency (8.0 mM) whereas a further four analogues were inactive against PPM1D (data not shown). The thienylidene cyclopentanone, CCT007093, has the potential to act as a Michael acceptor with biological thiols and amines and has been reported (along with structurally related compounds) to be an inhibitor of androgenic hormones (Scanlon, 1973) .
It is common in the screening of chemical libraries to identify hits with known or suspected additional pharmacological effects or potential liabilities. Such hits can nevertheless prove useful as chemical probes or as starting points for chemistry programmes aimed at optimizing the desired effect and removing or minimizing the potential liability (Collins and Workman, 2006) . To determine whether the hit compounds exhibited potential for selective on-target activity, additional mechanistic profiling was carried out. Further, compound validation was carried out using full-length recombinant phospho-P38 as substrate in an in vitro phosphatase assay (Figure 3 ). All six compounds described above exhibited some inhibitory activity on PPM1D, although this was less obvious for CCT071835 and CCT010971. The effects of the six hits on cell viability were also determined using MCF-7 and HeLa cells. Four compounds showed no growth inhibitory effects, presumably because of poor cell permeability. CCT000913 killed both cell lines with similar potency (SF 50 value of 1.0 and 1.8 mM for MCF-7 and HeLa cells respectively), indicating a lack of specificity (Supplementary Figure 2 ). Conversely, CCT007093 showed specificity for MCF-7 cells, reducing viability by 40% after 2 days with no observable effect on the growth of HeLa cells (Figure 4a ). Finally, using a similar Delfia assay, neither CC000913 nor CCT007093 was shown to inhibit the phosphatase activity of PPM1A (by primary structure comparison, the closest protein relative of PPM1D) at concentrations as high as 100 mM (data not shown).
PPM1D inhibitor-mediated cell death is dependant on P38 kinase activity We examined whether CC000913 and CCT007093 could mimic the effect of PPM1D RNAi in activating P38 Chemical inhibitors of PPM1D S Rayter et al kinase and whether activation of P38 kinase contributed to PPM1D inhibitor-mediated cell death. First, we showed that the two compounds induced phosphorylation of P38 in MCF-7 and HeLa cell lines (Figure 4b ). Despite a lack of selectivity, CCT000913 was able to elicit an increase in P38 phosphorylation in both HeLa and MCF-7 cells. The more selective compound, CCT007093, induced P38 phosphorylation at 4 h postexposure in MCF-7 cells (sensitive to PPM1D inhibition), rising to a peak at 8 h and then decreasing to basal levels by 24 h, possibly reflecting the unstable nature of the compound in a cellular environment. Consistent with the selectivity observed with RNAi silencing, CCT007093 did not induce P38 phosphorylation in HeLa cells (relatively resistant to PPM1D inhibition).
To determine whether dependence on P38 was related to the mechanism of action of the inhibitors, we chronically inhibited P38 with SB203580 for 24 h before administering either CC000913 or CCT007093 (Figure 4a ). Cell viability assays carried out at 48 h after the initial exposure to PPM1D inhibitor demonstrated that SB203580 could rescue the loss of viability in MCF-7 cells after CCT007093 exposure, reflecting P38 dependence and the specificity of this PPM1D inhibitor. Treatment of MCF-7 cells with SB203580 led to a 20-fold increase in the SF 50 of CC000913 (Supplementary Figure 2) .
Selectivity of PPM1D inhibitors on human tumour cell lines
We assessed the ability of CCT007093 to mimic the effect of PPM1D RNAi on cell viability in our panel of cell lines characterized for PPM1D expression. Using 
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S Rayter et al colony formation assays, the potent and selective effect of CCT007093 on human cell lines overexpressing PPM1D was confirmed ( Figure 5 ; Table 1 ). Therefore, the compound we identified as an enzymatic inhibitor in vitro mimics the effect of reducing PPM1D expression by RNAi gene silencing in cells.
Discussion
It has become a central tenet of modern cancer drug development that treatment should, and can be, tailored to the genetic changes in a tumour (Collins and Workman, 2006) . The established efficacy of therapeutics targeting proteins required for tumour viability, such as trastuzumab, and the promise of synthetic lethal approaches exemplified by poly-(ADP-ribose)polymerase inhibition (Brody, 2005) illustrate this point. Surviving Fraction (%) Figure 5 The PPM1D inhibitor CCT007093 selectively and potently inhibits human tumour cell lines that overexpress PPM1D. Colony formation assays were performed with the initial exposure to CCT007093 occurring 24 h after cell plating. Culture media and CCT007093 were replenished every 4 days thereafter. Surviving fraction was calculated by comparison to DMSO-treated cells. 
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PPM1D is a phosphatase gene that is amplified and overexpressed in a significant fraction of a number of cancer types. As such, it is a potential target for the development of specific inhibitors that might have utility as cancer therapeutics (Harrison et al., 2004) . Here, we describe significant progress towards the further validation of PPM1D as a therapeutic target alongside the identification of an agent that selectively kills cells that overexpress this protein.
The work described here has bolstered the case for the development of a therapeutic agent targeting PPM1D catalytic activity. Others have provided evidence that PPM1D is a candidate therapeutic target in many cancers. Notably, Bulavin et al. (2004) have elegantly demonstrated the suppression of mammary tumorigenesis using a Ppm1d
À/À mouse model. We have extended these findings to a human setting where PPM1D is endogenously overexpressed in human tumour cells. Using RNAi, we have demonstrated an important proof-of-principle, that specific reduction of PPM1D overexpression in human tumour cells can selectively reduce viability. Furthermore, we have confirmed that this loss of viability is P38 dependent, highlighting the probability that any clinical use of a PPM1D inhibitor would not only require PPM1D overexpression but also an intact P38 pathway. While others have already attempted to show the value of PPM1D inhibition in human tumour cells Belova et al., 2005) , we believe that the experiments described here (Figure 1 ) are the first demonstration of the effects of significant specific and selective PPM1D inhibition in human tumour cells.
To identify inhibitors of PPM1D phosphatase activity, we utilized the AlphaScreen format. We believe this to be the first reported use of this system to detect protein phosphatase activity in a high-throughput screen. This screen yielded a number of chemical inhibitors of PPM1D catalytic activity. While much effort has been invested into deriving inhibitors of protein kinases, few specific phosphatase inhibitors have been identified (Schmid and Woscholski, 2004) . This has been ascribed to the three-dimensional structure of the catalytic site of phosphatase enzymes which, when compared to the majority of kinases, have smaller, shallower, active sites making specific inhibition problematic (Harrison et al., 2004) . Nevertheless, the screening strategy that we adopted was successful in allowing the identification of specific inhibitors.
By examining the effect of CCT007093 on human tumour cells, we have shown that we are able to identify specific and selective chemical PPM1D inhibitors. CCT007093 was notable in its ability to mimic the effects of gene-specific PPM1D RNAi, both in its selectivity for human tumour cells that overexpress PPM1D and also by its reliance on an integral P38 pathway. It is interesting to note the greater potency of CCT007093 in cells than in the AlphaScreen assay. This could be due to the cellular accumulation of CCT007093, its metabolic conversion to a more active compound or an additional off-target effect on cellular thiol concentrations. However, major off-targets effects are unlikely given the evidence presented here for a selective cellular effect of the compound which phenocopies RNAi of PPM1D.
CCT007093 may find utility as an experimental tool to further dissect the downstream targets of PPM1D/ P38. Given the growing number of PPM1D substrates and dependant pathways (see 'Introduction'), it will be important to identify the dominant mechanisms in play when PPM1D overexpression is pathogenic. Much of this work can be carried out using methods such as RNAi. However, the effects caused by downregulation of gene expression and pharmacological inhibition are not identical. A small molecule inhibitor will allow therapeutic approaches to be modelled more effectively, including a potential use in in vivo studies.
It is possible that CCT007093 may have limitations as a drug development candidate. CCT007093 is a Michael acceptor and may have effects on cellular viability by its interaction with cellular nucleophiles. Such effects are not uncommon in hits identified in high-throughput screens or compound libraries (Collins and Workman, 2006) . Despite these potential effects, CCT007093 is able to elicit inhibition of PPM1D in cells (as assessed by phospho-P38 measurement) and consistent with the hypothesis that high PPM1D expression drives tumorigenesis, CCT007093 is selective for cancer cell lines that overexpress PPM1D. This work suggests that selective PPM1D inhibitors can be identified and that screening of additional chemical libraries using the AlphaScreen assay format described here may yield better development candidates.
In conclusion, the work described here further validates PPM1D as a potential therapeutic target in human tumours. Our identification of a small molecule that is selective in killing PPM1D overexpressing cells raises the exciting possibility of developing selective therapeutic agents targeting PPM1D which could be used for the treatment of substantial numbers of cancers.
Materials and methods

Cell lines
Cell lines were obtained from ATCC and maintained according to the supplier's instructions. Transfections were carried out using Lipofectamine 2000 (Invitrogen, Paisley, UK), according to the manufacturer's instructions. For shortterm viability assays, cell number was assessed using a Coulter Counter (Beckman Coulter, High Wycombe, UK).
Plasmids pSUPER constructs for RNAi were generated as described by Brummelkamp et al. (2002) . Target sequences were as follows: PPM1D 5 0 -AGAGAACGAATCGAAGGAC-3 0 and control 5 0 -CATGCCTGATCCGCTAGTC-3 0 . The control target sequence does not correspond to any complementary sequence in the human genome. The PPM1D-enhanced green fluorescent protein (eGFP) construct was generated by subcloning PCRamplified and sequenced full-length PPM1D cDNA into pEGFP-N1 (Clontech, Mountain View, CA, USA). For expression in Escherichia coli, PPM1D and P38 cDNAs were cloned into pRSET-A (Invitrogen, USA).
Antibodies
Anti-phospho-P38 (Thr 180 /Tyr 182 ) mouse monoclonal antibody (clone 28B10, #9216) anti-P38 rabbit polyclonal antibody (#9212) and anti-phospho-ATF2 (Thr 71 ) polyclonal antibody (#9221) were purchased from Cell Signaling Technology and New England Biolabs (UK) Ltd. Anti-b-tubulin mouse monoclonal antibody was purchased from Sigma. Anti-PPM1D polyclonal antibody was generated by immunizing rabbits with a synthetic peptide corresponding to residues at the C terminus of human PPM1D (N-APVPRRALGLPATP TLAGVGP-C).
Colony formation assay Cells were transfected with a pSUPER plasmid and an additional plasmid expressing the blasticidin resistance gene (pEFBsd, Invitrogen) in a molar ratio of 10:1. Cells were plated in 10 cm plates 24 h after transfection. Blasticidin selection (5 mg/ml) was initiated 48 h post-transfection and replenished every 3 days. Colonies werefixed in methanol and stained with crystal violet after 14 days. Colonies were quantified on a Colcount (Oxford Optronix, Oxford, UK) and the surviving fraction (SF) determined.
Generation of recombinant proteins
pRSET-A-PPM1D or pRSET-A-P38 transformed E. coli. (BL21-CodonPlus (DE3)-RP, Stratagene, La Jolla, CA, USA) were treated with isopropyl-b-D-thiogalactopyranoside (0.1-0.5 mM) for 24 h at 161C, in L-broth. Polyhistidinetagged protein was purified using immobilized metal-affinity chromatography and dialysed accordingly. PPM1D phosphatase activity was measured using p-nitrophenol substrate. Recombinant P38 was autophosphorylated by incubation in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer (50 mM, pH 7.5), NaCl (150 mM), MgCl 2 (40 mM), dithiothreitol (DTT) (1 mM) and ATP (200 mM) for 30 min at 371C. After dialysis and concentration, phosphorylation of P38 was assessed by western blotting and kinase activity was confirmed using GST-ATF2 as substrate (kind gift from Professor CJ Marshall, The Institute of Cancer Research, UK).
In vitro phosphatase assay Recombinant PPM1D (20-50 pmol) was diluted in Tris buffer (50 mM, pH 8), NaCl (100 mM), b-mercaptoethanol (1 mM) or DTT (1 mM) and treated with MnCl 2 (0, 1, 10 and 20 mM) or MgCl 2 (0 and 40 mM). Where appropriate, inhibitors of PPM1D (10-50 mM) were added and the assay mix incubated for 30 min at room temperature. Recombinant phospho-P38 (200 pmol) was then added and the mixture incubated at 371C for 1 h. The reaction was quenched by the addition of excess ethylenediaminetetraacetic acid (EDTA), sodium dodecyl sulphate-sample loading buffer and boiling for 5 min at 951C followed by gel electrophoresis and western blotting.
AlphaScreen assay
Enzyme reactions were carried out in a final volume of 20 ml in 384-well polypropylene plates. rPPM1D (2 nM final concentration) was diluted in a buffer composed of 40 mM Tris-HCl (pH 8), 20 mM MgCl 2 , 1 mM DTT, 0.1% (v/v) Tween 20 and 10% (v/v) glycerol. PPM1D in buffer was then incubated with 30 mM (final concentration) of library compound or vehicle (dimethyl sulfoxide, DMSO) for 30 min at room temperature. Biotinylated P38 phosphopeptide (biotin-FGLARHTD-DEMT(p)GY(p)VATRWYRAPEI, corresponding to amino acids 169-196 of human P38) substrate (30 nM) was then added. The enzyme mix was incubated for 20 min at room temperature and the reaction stopped by addition of 80 ml 50 mM EDTA (pH 7.5). Stopped reaction (10 ml) was transferred to a white 384-well Optiplate (PerkinElmer Life Sciences, Bucks, UK) and diluted 1:1 by volume with 10 mg/ml AlphaScreen streptavidin-coated donor bead, anti-mouse immunoglobulin G (IgG)-coated acceptor beads (both PerkinElmer Life Sciences) and 0.5 nM anti-phospho-P38 antibody (diluted in 40 mM Tris-HCl (pH 7.5), 2.5 mg/ml bovine serum albumin (BSA) and 10% (v/v) glycerol). All bead handling was carried out in low-light conditions. Plates were sealed and stored overnight in the dark and then read on a Packard Fusion plate reader. Primary screening data were analysed using Excel (Microsoft, USA) and subsequently processed using ActivityBase (IDBS, Guildford, UK). Percentage inhibition was calculated as 100À(S/B Â 100), where S represents counts in the compound well and B represents counts in the no enzyme wells. Z 0 and Z factors were determined (Zhang et al., 1999) .
Delfia biochemical assay
The enzyme reaction (total volume 25 ml) was carried out in 96-well polypropylene plates containing rPPM1D (4 nM), biotinylated phospho-P38 peptide (100 nM), either DMSO (2.5%, v/v) or compound (in the range 0-250 mM in 2.5% DMSO) and assay buffer (50 mM Tris-HCl (pH 8), 20 mM MgCl 2 , 1 mM DTT and 0.02% (v/v) Tween 20). The reaction was incubated for 30 min at room temperature and stopped by the addition of buffer (125 ml) containing 40 mM EDTA, 0.05% (v/v) Tween 20 and 0.1% (w/v) BSA in Tris-buffered saline ( Â 10 concentration, Sigma, UK). An aliquot (100 ml) of the reaction mix was transferred to a black neutravidin-coated plate (Perbio, Loughborough, UK) and incubated for 1 h on a shaker at room temperature. The plates were washed four times with wash buffer (25 mM Tris-HCl (pH 8), 150 mM NaCl, 0.1% (v/v) Tween 20) and incubated for 1 h as before with antibody mix (100 ml) consisting of primary antibody (4 nM) and europium-labelled anti-mouse IgG (0.25 mg/ml) diluted in Delfia assay buffer. The plates were washed again and enhancement solution (PerkinElmer Life Sciences, Waltham, MA, USA, 100 ml/well) added. The plate was read on a Victor2 1420 multilabel counter (PerkinElmer Life Sciences) using a time-resolved measurement mode reading fluorescence at 615 nM.
Chemical libraries
The initial compound library used contained a selection of diverse small molecules either purchased from commercial suppliers, archived in-house or obtained through Cancer Research UK. The National Cancer Institute Developmental Therapeutics Program Diversity Set was also screened (http:// dtp.nci.nih.gov/branches/dscb/diversity_explanation.html).
